MDCX · Medicus Pharma Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $2.70M | - | $564.1K | $1.28M | $321.4K | - | - | - |
| SG&A | $5.89M | - | $1.77M | $2.28M | $1.39M | - | - | - |
| Total Operating Expenses | $8.60M | - | $2.33M | $3.55M | $1.71M | - | - | - |
| D&A | - | - | - | - | - | - | - | - |
| Operating Income | ($8.60M) | - | ($2.33M) | ($3.55M) | ($1.71M) | - | - | - |
| Interest Expense | $0 | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | ($9.04M) | - | ($2.28M) | ($3.63M) | ($1.71M) | - | - | - |
| EPS - Basic | ($0.31) | - | ($0.24) | ($0.43) | ($0.21) | - | - | - |
| EPS - Diluted | ($0.31) | - | ($0.24) | ($0.44) | ($0.21) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.37M | $8.71M | $8.66M | $9.67M | $3.98M | $4.16M | $1.72M | $267.7K |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.28M | $3.44M | $2.03M | $1.77M | $2.04M | $1.28M | $210.8K | - |
| Current Assets | $7.28M | $9.89M | $9.78M | $11.00M | $5.09M | $5.38M | $1.89M | - |
| Total Assets | $7.43M | $10.06M | $9.98M | $11.93M | $5.66M | $5.65M | $1.89M | - |
| Current Liabilities | $5.95M | $9.94M | $10.66M | $8.54M | $3.34M | $2.31M | $781.6K | - |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.00M | $10.02M | $10.78M | $8.69M | $3.51M | $2.51M | $781.6K | - |
| Stockholders' Equity | $1.33M | ($67.6K) | $3.13M | $3.25M | $2.15M | $3.13M | $1.11M | ($12.19M) |
| Retained Earnings | ($73.39M) | ($64.35M) | ($5) | ($40.18M) | ($34.01M) | ($28.90M) | ($17.75M) | - |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.97M) | - | - | - | ($1.18M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $6.83M | - | - | - | $0 | - | - | - |
| CapEx | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q4 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -121.7% | - | -22.8% | -30.4% | -30.2% | - | - | - |
| Return on equity | -681.9% | - | -72.7% | -111.8% | -79.5% | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 1.22 | 1.00 | 0.92 | 1.29 | 1.53 | 2.33 | 2.42 | - |
| Quick ratio | 1.22 | 1.00 | 0.92 | 1.29 | 1.53 | 2.33 | 2.42 | - |
| Cash ratio | 1.07 | 0.88 | 0.81 | 1.13 | 1.19 | 1.81 | 2.20 | - |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - |
| Equity multiplier | 5.60 | -148.94 | 3.18 | 3.67 | 2.63 | 1.80 | 1.70 | - |
| Liabilities / Assets | 0.81 | 1.00 | 1.08 | 0.73 | 0.62 | 0.44 | 0.41 | - |
| Efficiency | ||||||||
| Asset turnover | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | 10.2x | - | 7.0x | 7.5x | 14.0x | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -403.5% | - | - | - | - | - | - | - |
| Net income growth (YoY) | -429.6% | - | - | - | - | - | - | - |
| EPS growth (YoY) | -47.6% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -38.3% | - | - | - | - | 182.0% | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Medicus Pharma Ltd. against the 5 most active filers in the same SIC group.